Skip to main content
main-content

01.12.2016 | Short report | Ausgabe 1/2016 Open Access

Tobacco Induced Diseases 1/2016

Ankle-brachial index and eicosapentaenoic acid/arachidonic acid ratio in smokers with type 2 diabetes mellitus

Zeitschrift:
Tobacco Induced Diseases > Ausgabe 1/2016
Autoren:
Kenta Okada, Kazuhiko Kotani, Shun Ishibashi
Wichtige Hinweise

Competing interests

The authors declare that they have no conflicts of interest.

Authors’ contributions

KO researched the data, wrote the manuscript, and contributed to the discussion; KK analyzed the data and edited and reviewed the manuscript; and SI contributed to the discussion and reviewed the manuscript. All authors read and approved the final manuscript.
Abbreviations
AA
arachidonic acid
ABI
ankle-brachial index
CVD
cardiovascular disease
DM
diabetes mellitus
EPA
eicosapentaenoic acid
HbA1c
hemoglobin A1c
PAD
peripheral arterial disease
SBP
systolic blood pressure
T2DM
type 2 diabetes mellitus

Findings

Background

Smokers have an increased risk of peripheral arterial damage, which is associated with cardiovascular disease (CVD) events in patients with diabetes mellitus (DM) [ 1]. Multi-faceted studies of subclinical peripheral arterial damage are thus important for prevention of CVD in patients with DM. Assessment of peripheral arterial damage is often conducted noninvasively using the ankle-brachial index (ABI) [ 2, 3]. Although ABI < 0.9 has diagnostic value for peripheral arterial disease (PAD) [ 2, 3], a low-to-borderline level of ABI (0.9–1.1) is also associated with increased risk of CVD events and related mortality [ 4, 5].
A low ratio of serum eicosapentaenoic acid to arachidonic acid (EPA/AA) has also been correlated with CVD events in patients with DM [ 6, 7]. An additional study reported that the EPA/AA ratio was positively associated with the ABI level in hospitalized patients, although it did not take into account smoking habits or DM pathology [ 8]. Recently, we reported that a low EPA/AA ratio is often seen in elderly patients with type 2 DM (T2DM), particularly in smokers [ 9]. However, the association between the ABI and EPA/AA ratio has not been elucidated; therefore, in the present study, we aimed to investigate the correlation between ABI and EPA/AA among smokers with T2DM.

Subjects and methods

Study participants

A cross-sectional study of 116 smoking and non-smoking T2DM patients (2 groups of 50 men and 8 women, mean age 59 yr in each group) who visited the Jichi Medical University Hospital, Shimotsuke, Japan for more 1 yr was conducted from April to September 2014. Smoking habits were confirmed via self-reports. Current smoking status was designated as either smoking or not smoking. None of the patients were taking medications containing EPA or AA. We excluded patients with a history of CVD events, recent acute illness, systemic inflammatory disease, severe nephropathy (i.e., stage 3–5), liver dysfunction, type 1 DM, and PAD. The study was approved by the Jichi Medical University Ethical Committee and informed consent was obtained from all patients.
Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, and/or anti-hypertensive drug use [ 10]. Nephropathy was defined as a urinary albumin-to-creatinine ratio > 30 mg/g creatinine, above the micro albuminuria level [ 11].

Data collection

Fasting blood samples were collected at the outpatient clinic to measure levels of glucose, hemoglobin A1c (HbA1c), total cholesterol, triglycerides, high-density lipoprotein cholesterol, EPA, and AA. A high-performance liquid chromatography system (HLA-723G8; Tosoh Corp., Tokyo, Japan) was used to measure HbA1c. Serum lipids were extracted by Folch’s method and the fatty acids (internal standard, tricosanoic acid [C23:0]) were methylated with boron trifluoride and methanol. EPA and AA levels in the methylated fatty acids were then analyzed by gas chromatography (GC-2010; Shimadzu Corp., Kyoto, Japan) with a capillary column (TC-70; GL Sciences Inc., Tokyo, Japan).
The ABI was determined using a pulse pressure analyzer (model BP-203RPEIII; Omron Colin Corp., Tokyo, Japan) as previously described [ 12]. ABI was determined based on the SBP in both the upper (brachial arterial) and lower (tibial arterial) arteries [ 13] and was calculated by dividing the ankle SBP by the brachial SBP. The patient population was divided into two ABI groups (<1.1 and ≥1.1) based on previous studies [ 4, 14].

Statistical analysis

Smoking and non-smoking patients were matched for age and sex. Comparisons between smoking and non-smoking groups were conducted using an unpaired t-test or chi-square test. Differences in parameters between ABI groups were analyzed using an unpaired t-test or chi-square test. Correlations between absolute ABI and the other parameters (including the EPA/AA ratio) were examined using a Pearson’s correlation test and stepwise multiple regression analysis (SPSS software; SPSS Inc., IL, USA). All parameters were included in the stepwise multiple regression model except for the EPA, which was not included due to multicollinearity with the EPA/AA ratio and the stronger correlation of the EPA/AA ratio with the ABI. Parameters with skewed distributions were log-transformed prior to all analyses. A p-value of <0.05 was considered to be significant.

Results

Clinical characteristics of the study population for the smoking and non-smoking groups are shown in Table  1. The HbA1c level and percentage with neuropathy complications were higher in the smoking group than in the non-smoking group.
Table 1
Clinical characteristics of the study population by current smoking habit
Parameter
Non-smoker ( n = 58)
Smoker ( n = 58)
p
Age, yr
59 ± 12
59 ± 10
0.91
Sex, male (%)
50 (86 %)
50 (86 %)
1.00
Body mass index, kg/m 2
26.3 ± 4.4
26.2 ± 4.5
0.88
Systolic blood pressure, mm Hg
131 ± 14
131 ± 11
0.80
Diastolic blood pressure, mm Hg
77 ± 11
79 ± 10
0.43
Antihypertensive drugs, n (%)
33 (57 %)
43 (74 %)
0.05
Glucose, mg/dL
149 ± 62
139 ± 42
0.29
Hemoglobin A1c, %
7.2 ± 1.0
7.6 ± 1.0
0.045*
Insulin injection, n (%)
15 (26 %)
14 (24 %)
0.83
Retinopathy, n (%)
18 (31 %)
23 (40 %)
0.33
Neuropathy, n (%)
24 (41 %)
36 (62 %)
0.03*
Nephropathy, n (%)
19 (33 %)
25 (43 %)
0.25
LDL cholesterol, mg/dL
97 ± 31
95 ± 33
0.73
HDL cholesterol, mg/dL
60 ± 17
55 ± 16
0.13
Triglycerides, mg/dL
114 (73–160)
125 (91–173)
0.19
Statin drugs, n (%)
21 (36 %)
22 (38 %)
0.85
AA, μg/mL
173 (151–212)
181 (152–234)
0.49
EPA, μg/mL
60 (41–96)
52 (36–86)
0.28
EPA/AA ratio
0.37 (0.23–0.56)
0.29 (0.19–0.42)
0.08
Ankle-brachial index
1.14 ± 0.07
1.11 ± 0.09
0.07
Data are means ± standard deviations, medians (interquartile ranges), or numbers (%)
LDL low-density lipoprotein, HDL high-density lipoprotein, AA arachidonic acid, EPA eicosapentaenoic acid
* p < 0.05 for comparison between groups by smoking ( t-test or chi-square test)
Two patients with ABI < 0.9 (the defined PAD level) were included in the smoking group. In the smoking group, patients with ABI < 1.1 had significantly lower EPA/AA ratios than did those with ABI ≥ 1.1, while the AA and EPA alone did not show clear differences between patients with ABI < 1.1 and ≥ 1.1. The other parameters were not statistically different between the groups (Table  2). In contrast, patients with ABI ≤ 1.1 had a significantly higher HbA1c than did those with ABI ≥ 1.1 in the non-smoking group. There were no statistical differences in the other parameters, including EPA/AA, with ABI levels in the non-smoking group.
Table 2
Clinical characteristics of the study population by ABI (<1.1 and ≥ 1.1)
 
Non-smoker
p
Smoker
p
Parameter
ABI < 1.1 ( n = 17)
ABI ≥ 1.1 ( n = 41)
ABI < 1.1 ( n = 26)
ABI ≥ 1.1 ( n = 32)
Age, yr
56 ± 14
60 ± 11
0.21
58 ± 10
60 ± 11
0.61
Sex, male (%)
15 (88 %)
35 (85 %)
0.77
22 (85 %)
28 (88 %)
0.75
Body mass index, kg/m 2
26.5 ± 5.6
26.2 ± 3.9
0.77
25.5 ± 3.8
26.7 ± 5.0
0.31
Systolic blood pressure, mm Hg
133 ± 17
130 ± 13
0.45
131 ± 10
132 ± 12
0.77
Diastolic blood pressure, mm Hg
80 ± 13
76 ± 10
0.22
79 ± 9
78 ± 10
0.76
Antihypertensive drugs, n (%)
12 (71 %)
21 (51 %)
0.18
20 (77 %)
23 (72 %)
0.66
Glucose, mg/dL
157 ± 39
146 ± 70
0.55
137 ± 42
140 ± 43
0.74
Hemoglobin A1c, %
7.7 ± 1.2
7.0 ± 0.8
0.01*
7.6 ± 1.0
7.5 ± 1.0
0.82
Insulin injection, n (%)
7 (41 %)
8 (20 %)
0.09
3 (12 %)
11 (34 %)
0.06
Retinopathy, n (%)
6 (35 %)
12 (29 %)
0.65
9 (35 %)
14 (44 %)
0.48
Neuropathy, n (%)
10 (59 %)
14 (34 %)
0.08
10 (38 %)
15 (47 %)
0.52
Nephropathy, n (%)
5 (29 %)
14 (34 %)
0.73
16 (62 %)
20 (63 %)
0.94
LDL cholesterol, mg/dL
96 ± 38
97 ± 28
0.88
95 ± 39
94 ± 28
0.95
HDL cholesterol, mg/dL
61 ± 18
59 ± 16
0.68
52 ± 14
57 ± 18
0.23
Triglycerides, mg/dL
127 (79–217)
107 (69–144)
0.18
139 (116–233)
118 (83–159)
0.09
Statin drugs, n (%)
6 (35 %)
15 (37 %)
0.93
13 (50 %)
9 (28 %)
0.09
AA, μg/mL
176 (144–214)
173 (150–210)
0.51
191 (158–244)
180 (134–227)
0.18
EPA, μg/mL
64 (46–114)
60 (41–97)
0.26
49 (33–69)
68 (41–96)
0.07
EPA/AA ratio
0.44 (0.21–0.75)
0.37 (0.23–0.55)
0.56
0.25 (0.16–0.40)
0.34 (0.20–0.69)
0.03*
Ankle-brachial index
1.06 ± 0.04
1.17 ± 0.05
<0.01**
1.03 ± 0.06
1.18 ± 0.05
<0.01**
Data are means ± standard deviations, medians (interquartile ranges), or numbers (%)
LDL low-density lipoprotein, HDL high-density lipoprotein, AA arachidonic acid, EPA eicosapentaenoic acid
* p < 0.05, ** p < 0.01 for comparison between ABI groups ( t-test or chi-square test)
Correlations of absolute ABI with the other parameters are listed in Table  3. Pearson’s correlation tests found that EPA and the EPA/AA ratio were significantly and positively correlated with ABI levels in the smoking group, while HbA1c was significantly and negatively correlated with ABI levels in the non-smoking group. Stepwise multiple regression analysis revealed that the EPA/AA ratio was independently, significantly, and positively correlated with ABI levels and that use of statin drugs was inversely correlated with ABI levels in the smoking group, while HbA1c was independently, significantly, and negatively correlated with ABI levels in the non-smoking group.
Table 3
Correlations between the absolute value of the ankle-brachial index and other parameters
 
Non-smoker
Smoker
Parameter
r ( p)
β ( p)
r ( p)
β ( p)
Age, yr
0.23 (0.09)
NE
0.06 (0.67)
NE
Sex, male (%)
0.14 (0.31)
0.19 (0.12)
0.03 (0.81)
NE
Body mass index, kg/m 2
−0.07 (0.61)
NE
0.05 (0.70)
NE
Systolic blood pressure, mm Hg
−0.05 (0.71)
NE
−0.04 (0.78)
NE
Diastolic blood pressure, mm Hg
−0.11 (0.41)
NE
−0.13 (0.35)
NE
Antihypertensive drugs, n (%)
−0.15 (0.27)
NE
−0.10 (0.45)
NE
Glucose, mg/dL
−0.16 (0.25)
NE
0.03 (0.85)
NE
Hemoglobin A1c, (%)
−0.46 (<0.01**)
−0.45 (<0.01**)
0.01 (0.95)
NE
Insulin injection, n (%)
−0.21 (0.12)
NE
0.19 (0.14)
0.26 (0.06)
Retinopathy, n (%)
−0.02 (0.91)
NE
−0.08 (0.54)
NE
Neuropathy, n (%)
−0.18 (0.18)
NE
−0.04 (0.79)
NE
Nephropathy, n (%)
0.08 (0.58)
NE
−0.05 (0.73)
NE
LDL cholesterol, mg/dL
−0.01 (0.95)
NE
−0.05 (0.72)
NE
HDL cholesterol, mg/dL
0.06 (0.67)
NE
0.22 (0.10)
NE
Triglycerides, mg/dL
−0.22 (0.11)
−0.16 (0.17)
−0.16 (0.27)
NE
Statin drugs, n (%)
−0.12 (0.37)
NE
−0.15 (0.26)
−0.31 (0.03*)
AA, μg/mL
0.04 (0.78)
−0.13 (0.32)
EPA, μg/mL
−0.19 (0.16)
0.28 (0.04*)
EPA/AA ratio
0.05 (0.73)
NE
0.31 (0.02*)
0.41 (<0.01**)
LDL low-density lipoprotein, HDL high-density lipoprotein, AA arachidonic acid, EPA eicosapentaenoic acid, NE not extracted; −: not used in the analysis. Data are Pearson’s r correlation coefficients and standardized β coefficients from stepwise multiple regression analysis
* p < 0.05, ** p < 0.01

Discussion

We found that the EPA/AA ratio was lower in patients with ABI < 1.1 than in those with ABI ≥ 1.1, with a positive correlation between the EPA/AA ratio and ABI in smokers with T2DM. To our knowledge, a relationship between the EPA/AA ratio and ABI level among smokers or non-smokers with T2DM has not previously been reported. Accordingly, the results of this study suggest that the EPA/AA ratio may be associated with subclinical PAD in smokers with T2DM.
By contrast of n-3 fatty acids, particularly EPA, n-6 fatty acids, particularly AA, impair peripheral arteries by creating vasoactive oxygen radicals and promoting cyclooxygenase metabolism [ 15, 16]. In smokers, a delayed conversion of AA to eicosanoids is known [ 1719], this may result in endothelial dysfunction in peripheral arteries [ 20]. This is a possible mechanism for a positive correlation between the EPA/AA ratio and ABI levels in smokers with DM, although this requires further research.
Based on the results of our stepwise regression model, ABI was inversely associated with the use of statin drugs in the smoking group. Statins are often prescribed for patients with DM, particularly when the patients may have complications of DM. As a result, patients with subclinical PAD may use statins. This is only a hypothesis; however, similar results were reported in a previous study [ 21].
The present study had certain limitations. It was a cross-sectional study with a small sample size; thus, further intervention and a placebo control study are needed. Additionally, as there was no information regarding dietary fish consumption, smoking dose, or smoking duration (e.g., the Brinkman index), and because the cigarette type was not investigated in detail, these factors could not be considered in our analysis.

Conclusions

In summary, the EPA/AA ratio may be associated with subclinical PAD in smokers with T2DM. The utility of measuring the EPA/AA ratio along with ABI should be further investigated in future studies.

Acknowledgments

No funding was received for this study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no conflicts of interest.

Authors’ contributions

KO researched the data, wrote the manuscript, and contributed to the discussion; KK analyzed the data and edited and reviewed the manuscript; and SI contributed to the discussion and reviewed the manuscript. All authors read and approved the final manuscript.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

Tobacco Induced Diseases 1/2016 Zur Ausgabe